Balanced Portfolio Recommendation: Trim Neuren Pharmaceuticals (NEU)
After much higher than expected sales results, we recommend a trim of 1% (one quarter) of the holding
After much higher than expected sales results, we recommend a trim of 1% (one quarter) of the holding
Recent earnings results from Canadian uranium-fuel giant, Cameco saw a significant increase in nuclear energy demand and a potential supply gap in the immediate future. This demand is driven by global calls for clean, secure, and affordable energy with Nuclear being the stop-gap solution for base load electricity until new energy technologies become more commercial
Macquarie Bank is set to announce earnings, consistently demonstrating a remarkable record of exceeding expectations. MQG is a cornerstone in our portfolios, showcasing reliable performance. We advise purchasing a 2%-4% allocation of MQG shares on Thursday, anticipating a potential gap-up at Friday’s market open, following the release of positive updates.
After a 56% rally on China banning exports to foreign countries, Ex-China graphite assets have enjoyed a spike in prices over the last few days
CSL is also very close to trial results for a heart attack drug CSL112, a key pipeline product for CSL. Base case assumptions imply a valuation of around $30/share.
Amid the Hamas-Israel conflict, oil markets will be volatile. Short-term price hikes are likely. Investing in Woodside offers a hedge against such disruptions. Currently undervalued, Woodside also boasts a strong dividend yield, making it an attractive and strategic investment choice in these uncertain times.
A recent rally in the underlying coal price and broker upgrades for Stanmore have seen consensus price targets shift to around $4, We are generally bullish the energy sector and see SMR as a short term buy with a 10% trailing stop